GlassScriptPhysician profile
Arpan Narendra Desai
NPI 1184609638
$3,069.21
in general payments reported to CMS, 2019-2025
29 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $560 · 2021: $526 · 2022: $273 · 2023: $291 · 2024: $93.07 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $537.06 | 2019-2023 | Xtampza |
| Abbott Laboratories | $329.21 | 2019-2023 | Octrode |
| Medtronic, INC. | $241.06 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Scilex Pharmaceuticals INC. | $192.87 | 2019-2023 | Ztlido |
| Medtronic USA, INC. | $186.22 | 2019-2020 | |
| Pacira Therapeutics, INC. | $169.89 | 2019 | |
| Boston Scientific Corporation | $148.76 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $139.96 | 2019-2021 | |
| Pfizer INC. | $126.07 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.32 | 2019-2023 | Relistor |
| Globus Medical, INC. | $120.23 | 2025 | Senza |
| Arbor Pharmaceuticals, INC. | $98.24 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $85.93 | 2023 | Horizant |
| Assertio Therapeutics, INC. | $85.90 | 2019-2020 | |
| Horizon Therapeutics Plc | $73.87 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $67.03 | 2019 | |
| Forte Bio-Pharma LLC | $65.08 | 2019-2021 | |
| Almatica Pharma LLC | $59.23 | 2021 | |
| Mdd US Operations, LLC | $34.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.13 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $24.88 | 2023 | Iovera, Zilretta, Exparel |
| Fidia Pharma USA INC. | $20.18 | 2022 | |
| Hydrocision, INC. | $17.38 | 2024 | Tenjet |
| Nevro Corp. | $16.82 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $16.60 | 2019 | |
| Ibsa Pharma INC. | $13.01 | 2023 | Tirosint, Licart |
| Mml US, INC. | $12.02 | 2025 | Reactiv8 |
| Currax Pharmaceuticals LLC | $4.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arpan Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.